Rivka Friedland, Khalaf Kridin, Arnon Dov Cohen, Daniel Landau, Dan Ben-Amitai
Issues - Marzo 2022
Rivka Friedland, Khalaf Kridin, Arnon Dov Cohen, Daniel Landau, Dan Ben-Amitai
Zhaoyang Wang, Yunliu Chen, Xin Xiang, Yang Gu, Mutong Zhao, Yuanxiang Liu, Yachen Wang, Zigang Xu
Systemic methotrexate treatment in 42 children with severe plaque psoriasis: A retrospective study in China
Dermatology. 2022 Feb 17;1-9Alessandra Narcisi, Mario Valenti, Andrea Cortese, Francesco Toso, Giulia Pavia, Luigi Gargiulo, Riccardo Borroni, Antonio Costanzo
Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study
Dermatol Ther. 2022 Feb;35(2):e1522Chun-Yu Cheng
Risk of incident cataract in patients with psoriasis: A population-based cohort study
J Dermatol. 2022 Mar;49(3):359-36Michela Starace, Aurora Alessandrini, Matilde Iorizzo, Ambra D’Altobrando, Tiziano Ferrari, Francesca Bruni, Bianca Maria Piraccini
A pilot study of intralesional methotrexate injections versus triamcinolone acetonide in patients affected by nail matrix psoriasis
Clin Exp Dermatol. 2022 Feb 2022 Feb 3. Online ahead of printMarieke M B Seyger, Matthias Augustin, Michael Sticherling, Teresa Bachhuber, Juanzhi Fang, James Hetherington, James Lucas, Sophie Meakin, Craig Richardson, Amy S Paller
Physician-reported clinical unmet needs, burden and treatment patterns of paediatric psoriasis patients: A US and EU real-world evidence study
Acta Derm Venereol. 2022 Feb 28;102:adv0066A Ruggiero, G Fabbrocini, E Cinelli, S S Ocampo Garza, E Camela, M Megna
Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice
Clin Exp Dermatol. 2022 Mar;47(3):561-56K B Gordon, M Lebwohl, K A Papp, H Bachelez, J J Wu, R G Langley, A Blauvelt, B Kaplan, M Shah, Y Zhao, R Sinvhal, K Reich
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis
Br J Dermatol. 2022 Mar;186(3):466-47Francesco Bellinato, Paolo Gisondi, Giampiero Girolomoni
Risk of lymphohematologic malignancies in patients with chronic plaque psoriasis: A systematic review with meta-analysis
J Am Acad Dermatol. 2022 Jan;86(1):86-96Nina Magnolo, Külli Kingo, Vivian Laquer, John Browning, Adam Reich, Jacek C Szepietowski, Deborah Keefe, Rafal Mazur, Prayashi Ghelani, Pascal Forrer, LindaAnn Wraith, Manmath Patekar
A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results
J Am Acad Dermatol. 2022 Jan;86(1):122-130Stefano Piaserico, Paolo Gisondi, Simone Cazzaniga, Sara Di Leo, Luigi Naldi
Assessing the Risk and Outcome of COVID-19 in Patients with Psoriasis or Psoriatic Arthritis on Biologic Treatment: A Critical Appraisal of the Quality of the Published Evidence
J Invest Dermatol. 2022 Feb;142(2):355-363L Penso, R Dray-Spira, A Weill, M Zureik, E Sbidian
Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1 326 312 patients in France
Br J Dermatol. 2022 Jan;186(1):59-68April W Armstrong, Ahmed M Soliman, Keith A Betts, Yan Wang, Yawen Gao, Vassilis Stakias, Luis Puig